Literature DB >> 21785050

Value of PET/CT in the management of liver metastases, part 1.

Ari Sacks1, Patrick J Peller, Devaki S Surasi, Luke Chatburn, Gustavo Mercier, Rathan M Subramaniam.   

Abstract

OBJECTIVE: Metastasis is the most common (95%) of liver lesions. Early diagnosis and staging are the keys to treatment planning and prognosis. There is a consistent benefit to the use of PET/CT for detecting hepatic, local, and distant metastases from a variety of primary malignancies, which can contribute to staging and ultimately helps to establish the best course of treatment and to determine prognosis.
CONCLUSION: For colorectal cancer, FDG PET and FDG PET/CT are particularly effective for identification of additional hepatic and extrahepatic metastases, frequently upstaging the tumor stage and affecting management. In addition, PET/CT is very useful in local ablative and systemic therapy assessment and surveillance for liver metastases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21785050     DOI: 10.2214/AJR.10.6331

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  18 in total

1.  Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinoma.

Authors:  Yukako Ichimiya; Krishna Alluri; Charles Marcus; Simon Best; Christine H Chung; Rathan M Subramaniam
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

2.  Preoperative imaging for hepatic resection of colorectal cancer metastasis.

Authors:  Timothy L Frankel; Richard Kinh Gian; William R Jarnagin
Journal:  J Gastrointest Oncol       Date:  2012-03

3.  Added diagnostic value of respiratory-gated 4D 18F-FDG PET/CT in the detection of liver lesions: a multicenter study.

Authors:  Cinzia Crivellaro; Elena De Ponti; Federica Elisei; Sabrina Morzenti; Maria Picchio; Valentino Bettinardi; Annibale Versari; Federica Fioroni; Miroslaw Dziuk; Konrad Tkaczewski; Renée Ahond-Vionnet; Guillaume Nodari; Sergio Todde; Claudio Landoni; Luca Guerra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-19       Impact factor: 9.236

4.  Contrast Enhanced Ultrasound in CT-undetermined Focal Liver Lesions.

Authors:  S W Sandrose; S Karstrup; O Gerke; S Rafaelsen
Journal:  Ultrasound Int Open       Date:  2016-11

5.  Role of 18F-FDG PET/CT vs CT-scan in patients with pulmonary metastases previously operated on for colorectal liver metastases.

Authors:  Victor Lopez-Lopez; Ricardo Robles; Roberto Brusadin; Asuncion López Conesa; Juan Torres; Domingo Perez Flores; Jose Luis Navarro; Pedro Jose Gil; Pascual Parrilla
Journal:  Br J Radiol       Date:  2017-10-27       Impact factor: 3.039

6.  Time to Progression of Pancreatic Cancer: Evaluation with Multi-Detector Computed Tomography.

Authors:  Su Joa Ahn; Seung Joon Choi; Hyung Sik Kim
Journal:  J Gastrointest Cancer       Date:  2017-06

7.  FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma.

Authors:  Vasavi Paidpally; Alin Chirindel; Christine H Chung; Jeremy Richmon; Wayne Koch; Harry Quon; Rathan M Subramaniam
Journal:  AJR Am J Roentgenol       Date:  2014-08       Impact factor: 3.959

8.  PET-avid hepatocellular adenomas: incidental findings associated with HNF1-α mutated lesions.

Authors:  Ser Yee Lee; T Peter Kingham; Maria D LaGratta; Jose Jessurun; Daniel Cherqui; William R Jarnagin; Michael D Kluger
Journal:  HPB (Oxford)       Date:  2015-12-11       Impact factor: 3.647

9.  Usefulness of respiratory-gated PET acquisition during delayed 18F-FDG PET/CT scanning for patients with liver metastases.

Authors:  Shota Watanabe; Kohei Hanaoka; Hayato Kaida; Tomoko Hyodo; Minoru Yamada; Masakatsu Tsurusaki; Kazunari Ishii
Journal:  Asia Ocean J Nucl Med Biol       Date:  2021

10.  Evaluation of Hybrid PET/MRI for Gross Tumor Volume (GTV) Delineation in Colorectal Cancer Liver Metastases Radiotherapy.

Authors:  Yan-Nan Zhang; Xin Lu; Zhen-Guo Lu; Li-Ping Fu; Jun Zhao; Zuo-Lin Xiang
Journal:  Cancer Manag Res       Date:  2021-07-06       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.